30-Day Pharmacokinetic Evaluation of IV versus Subcutaneous Administration of Immunoglobulin with and without Recombinant Human Hyaluronidase in Dogs

30-Day Pharmacokinetic Evaluation of IV versus Subcutaneous Administration of Immunoglobulin with and without Recombinant Human Hyaluronidase in Dogs

Previous clinical studies demonstrated that subcutaneous (SC) administration of recombinant human hyaluronidase (rHuPH20) followed by 10% human immunoglobulin is associated with a pharmacokinetic profile similar to intravenous (IV) administration.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2009-02, Vol.123 (2), p.S10-S10
Hauptverfasser: Leesch, V.W, Johnson, B.A, Cook, C.S, Yocum, R.C, Schiff, R.I, Muchitsch, E.M, Teschner, W
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Bioavailability
Immune system
Medical research
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Previous clinical studies demonstrated that subcutaneous (SC) administration of recombinant human hyaluronidase (rHuPH20) followed by 10% human immunoglobulin is associated with a pharmacokinetic profile similar to intravenous (IV) administration.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2008.12.051